OVERVIEW

Therapeutic Challenges in EGFR-Mutant NSCLC: Addressing Treatment Choices and Resistance is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
This educational activity is designed for medical oncologists, health-system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other clinicians involved and/or interested in the therapeutic management of patients with NSCLC.

Accreditation:
1.50 CME
1.50 CNE
1.50 CPE

Course Overview:
Compared with other cancers, NSCLC has shown a higher rate of genetic mutations. The most-frequently studied genetic alterations are the epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Both are involved in the receptor tyrosine kinase signaling pathway, a mechanism that contributes to cancer cell survival and proliferation. Between 80% and 90% of EGFR somatic mutations display a deletion to exon 19 (del19) and substitutions to exon 21 L858R. These mutations have provided a therapeutic target for EGFR tyrosine kinase inhibitors (TKIs), which have vastly expanded treatment opportunities for patients with EGFR+ NSCLC. Clinicians who treat patients with NSCLC need to understand the genetic targets of newer second-generation and third-generation EGFR TKIs.

This webcast aims to improve oncology clinicians’ ability to treat patients with EGFR+ NSCLC, specifically as it relates to incorporating newer therapies and clinical data into practice and actively monitoring and addressing treatment resistance and related adverse events.

Course Objectives:
Upon successful completion of this educational activity, participants should be better able to:

• Review the current and emerging clinical data regarding the treatment NSCLC that harbor genetic mutations such as EGFR, ALK, ROS1, and less commonly ERBB2, HER2, BRAF, KRAS, MET, TRK, and RET
• Determine the clinical relevance of emerging efficacy and safety data from trials evaluating targeted therapies and immune checkpoint inhibitors (alone or in combination) for NSCLC, SCLC, mesothelioma, and less common thoracic malignancies
• Evaluate the role of current and emerging biomarkers as predictive indicators for treatment selection and patient response
• Translate the latest evidence regarding molecularly targeted agents, immunotherapies, and predictive biomarkers to informed and personalized NSCLC treatment plans

Additional details will be posted as soon as they are available.